BioCryst Pharmaceuticals
Update in progressBCRX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on medicines for hereditary angioedema and other rare diseases. It markets RAPIVAB/RAPIACTA/PERAMIFLU (intravenous peramivir) for influenza and ORLADEYO (berotralstat) for HAE. It is developing BCX17725 for netherton syndrome, Avoralstat for diabetic macular edema, Navenibart for HAE, STAR-0310 for atopic dermatitis, and KLK5 inhibitors in early trials. Founded 1986; based in Durham, NC.
Company score
- Sentiment
- 0.51
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.43
- Governance
- 0.21
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.35
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Charles K. Gayer
- Founded1986
- Employees435
- Websitewww.biocryst.com
Identifiers
- ISINUS09058V1035
- FIGIBBG000BLYWX6
- LEI549300Z0INP1Z5NP6J59
- CUSIP09058V103
- CIK0000882796